CG Oncology, Inc.
CGONHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeCG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. With a market capitalization of $5.47B, it sits in mid-cap territory. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
Market Cap
$5.47B
Beta
0.28
P/E (TTM)
—
P/E (Fwd)
-20.43
EPS (TTM)
$-2.69
EPS (Fwd)
$-3.02
ROE
-26.4%
ROA
-17.7%
Cash
$1.03B
Total Debt
$8.8M
Free CF
-$113.7M
52W Change
41.3%
Annual Financials
Cash vs Debt
Where CGON stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CGON finished 12.71% below its 150-day moving average ($68.69) and 8.02% below its 200-day moving average ($65.19). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CGON overbought or oversold?
At the October 20, 2026 close, CGON's RSI(14) was 19.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $1.03B in cash comfortably exceeding the $8.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$113.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -26.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $191K (2022) to $4.0M (2025), reflecting a 2015% increase over the period.
The relatively low beta of 0.28 suggests CGON is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for CG Oncology, Inc. and its sector.